208 related articles for article (PubMed ID: 1555482)
21. [Thrombolysis with recombinant tissue-type plasminogen activator (rt-PA) in 13 children: a case series].
Schermer E; Streif W; Genser N; Frühwirth M; Trawöger R; Simma B
Wien Klin Wochenschr; 2000 Nov; 112(21):927-33. PubMed ID: 11144008
[TBL] [Abstract][Full Text] [Related]
22. (More than) doubling down: Effective fibrinolysis at a reduced rt-PA dose for catheter-directed thrombolysis combined with histotripsy.
Hendley SA; Bhargava A; Holland CK; Wool GD; Ahmed O; Paul JD; Bader KB
PLoS One; 2022; 17(1):e0261567. PubMed ID: 34982784
[TBL] [Abstract][Full Text] [Related]
23. SSR182289A enhances thrombolysis induced by fibrinolytic agents in rabbit models of venous and arterial thrombosis.
Visconte C; Sainte-Marie M; Lorrain J; Millet L; O'Connor SE; Schaeffer P; Herbert JM
J Thromb Haemost; 2004 Apr; 2(4):629-36. PubMed ID: 15102019
[TBL] [Abstract][Full Text] [Related]
24. Recombinant lys-plasminogen, but not glu-plasminogen, improves recombinant tissue-type plasminogen activator-induced coronary thrombolysis in dogs.
Mehta JL; Chen L; Nichols WW; Johannesen M; Bregengård C; Hedner U; Saldeen TG
J Am Coll Cardiol; 1995 Mar; 25(3):753-60. PubMed ID: 7860925
[TBL] [Abstract][Full Text] [Related]
25. Fibrinogen breakdown, long-lasting systemic fibrinolysis, and procoagulant activation during alteplase double-bolus regimen in acute myocardial infarction.
Stangl K; Laule M; Tenckhoff B; Stangl V; Gliech V; Dübel P; Grohmann A; Melzer C; Langel J; Wernecke KD; Baumann G; Ziemer S
Am J Cardiol; 1998 Apr; 81(7):841-7. PubMed ID: 9555772
[TBL] [Abstract][Full Text] [Related]
26. Single bolus administration of recombinant tissue plasminogen activator: effects on infarct related vessel patency, microvascular perfusion, and microvascular reocclusion in a canine model of thrombotic occlusion/reperfusion.
Longridge DJ; Follenfant MJ; Ford AJ
Cardiovasc Res; 1991 Mar; 25(3):184-91. PubMed ID: 1903080
[TBL] [Abstract][Full Text] [Related]
27. [Changes in systemic fibrinolysis and blood coagulation parameters in local thrombolysis with tissue plasminogen activator (rt-PA)].
Klein P; Roth FJ; Rieger H; Popov-Cenic S
Vasa; 1992; 21(3):249-52. PubMed ID: 1529628
[TBL] [Abstract][Full Text] [Related]
28. Enhancement of thrombolysis with tissue-type plasminogen activator by pretreatment with heparin.
Cercek B; Lew AS; Hod H; Yano J; Reddy NK; Ganz W
Circulation; 1986 Sep; 74(3):583-7. PubMed ID: 3091287
[TBL] [Abstract][Full Text] [Related]
29. A novel chimaeric derivative of saruplase, rscu-PA-40 kDA/Hir, binds to thrombin and exerts thrombus-specific fibrinolysis in arterial and venous thrombosis in dogs.
Schneider J; Hauser R; Hennies HH; Korioth J; Steffens G; Wnendt S
Thromb Haemost; 1997 Mar; 77(3):535-9. PubMed ID: 9066007
[TBL] [Abstract][Full Text] [Related]
30. Tissue plasminogen activator: a new thrombolytic agent.
Crabbe SJ; Cloninger CC
Clin Pharm; 1987 May; 6(5):373-86. PubMed ID: 3117481
[TBL] [Abstract][Full Text] [Related]
31. Prevention of early reocclusion after thrombolysis of copper coil-induced thrombi in the canine carotid artery: comparison of PEG-hirudin and unfractionated heparin.
Rübsamen K; Hornberger W
Thromb Haemost; 1996 Jul; 76(1):105-10. PubMed ID: 8819261
[TBL] [Abstract][Full Text] [Related]
32. Synergistic effect on thrombolysis of sequential infusion of tissue-type plasminogen activator (t-PA) single-chain urokinase-type plasminogen activator (scu-PA) and urokinase in the rabbit jugular vein thrombosis model.
Collen D; Stassen JM; De Cock F
Thromb Haemost; 1987 Oct; 58(3):943-6. PubMed ID: 3124288
[TBL] [Abstract][Full Text] [Related]
33. In vitro clot lysis as a potential indicator of thrombus resistance to fibrinolysis--study in healthy subjects and correlation with blood fibrinolytic parameters.
Colucci M; Scopece S; Gelato AV; Dimonte D; Semeraro N
Thromb Haemost; 1997 Apr; 77(4):725-9. PubMed ID: 9134650
[TBL] [Abstract][Full Text] [Related]
34. A randomized trial of a single bolus dosage regimen of recombinant tissue plasminogen activator in patients with acute pulmonary embolism.
Levine M; Hirsh J; Weitz J; Cruickshank M; Neemeh J; Turpie AG; Gent M
Chest; 1990 Dec; 98(6):1473-9. PubMed ID: 2123152
[TBL] [Abstract][Full Text] [Related]
35. Prevention of rethrombosis after coronary thrombolysis in a chronic canine model. II. Adjunctive therapy with r-hirudin.
Rote WE; Mu DX; Bates ER; Nedelman MA; Lucchesi BR
J Cardiovasc Pharmacol; 1994 Feb; 23(2):203-11. PubMed ID: 7511748
[TBL] [Abstract][Full Text] [Related]
36. [Does the result of thrombolysis with recombinant tissue-type plasminogen activator (rt-PA) in rabbits depend on the erythrocyte- and fibrin-content of a thrombus?].
Kirchhof K; Sikinger M; Welzel T; Zoubaa S; Sartor K
Rofo; 2004 Jan; 176(1):98-105. PubMed ID: 14712413
[TBL] [Abstract][Full Text] [Related]
37. The effect of thrombin inhibitors on tissue plasminogen activator induced thrombolysis in a rat model.
Klement P; Borm A; Hirsh J; Maraganore J; Wilson G; Weitz J
Thromb Haemost; 1992 Jul; 68(1):64-8. PubMed ID: 1514174
[TBL] [Abstract][Full Text] [Related]
38. Reduced dose bolus alteplase vs conventional alteplase infusion for pulmonary embolism thrombolysis. An international multicenter randomized trial. The Bolus Alteplase Pulmonary Embolism Group.
Goldhaber SZ; Agnelli G; Levine MN
Chest; 1994 Sep; 106(3):718-24. PubMed ID: 8082347
[TBL] [Abstract][Full Text] [Related]
39. A long-half-life and fibrin-specific form of tissue plasminogen activator in rabbit models of embolic stroke and peripheral bleeding.
Thomas GR; Thibodeaux H; Errett CJ; Badillo JM; Keyt BA; Refino CJ; Zivin JA; Bennett WF
Stroke; 1994 Oct; 25(10):2072-8; discussion 2078-9. PubMed ID: 8091454
[TBL] [Abstract][Full Text] [Related]
40. [Thrombolytic therapy of deep venous thrombosis with rt-PA].
Zimmermann R; Horn A; Harenberg J; Diehm C; Müller-Bühl U; Kübler W
Klin Wochenschr; 1988; 66 Suppl 12():137-42. PubMed ID: 3126342
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
